MOUNTAIN VIEW, Calif., Feb. 17, 2011 /PRNewswire/ — Clontech
Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc.,
today announced the release of the
Tet-Express Inducible Expression System, which provides the
quickest and simplest Tet-inducible expression technology yet. At
the heart of this new system is a cell membrane-permeable version
of Clontech’s Tet-Off® Advanced transcriptional activator
protein (the Tet-Express transactivator) that can enter cells
directly, i.e., without transfection. The Tet-Express system
eliminates the requirement for a double-stable cell line expressing
both the gene of interest and the tetracycline transactivator.
Instead, only the gene of interest is cloned into the cells; then
when gene expression is required, simply add the self-transducing
Tet-Express protein directly to the cells in order to turn on the
gene of interest. Since the Tet-Express protein binds and activates
expression in the absence of tetracyclines, doxycycline is not
required for gene activation, further simplifying the system.
Clontech has filed for patent protection for the Tet-Express
system.

Carol Lou, General Manager of Clontech Laboratories, Inc.,
comments: “Clontech has a long history of leadership in developing
technologies for gene delivery and expression. We are pleased to
continue and extend this history by adding the Tet-Express
Inducible Expression System to our portfolio of Tet System
Products, which are the gold standard for regulated gene
expression.”

For maximal expression and minimal background, the Tet-Express
Inducible Expression System contains Clontech’s latest and tightest
Tet System promoter, TRE3G, which is found in Clontech’s
Tet-On® 3G Expression Systems (developed and marketed under
a license from TET Systems GmbH and Co. KG)

‘/>”/>

SOURCE